Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a, Open-label, Dose-escalation/Expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia

Trial Profile

Phase 1/2a, Open-label, Dose-escalation/Expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PBCAR-0191 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Precision Biosciences
  • Most Recent Events

    • 06 Nov 2019 Interim results presenteded in a Precision Biosciences Media Release.
    • 06 Nov 2019 According to a Precision Biosciences media release, will host a live webcast of an investigator update event during the ASH Annual Meeting to discuss the presented data, beginning at 8:15 p.m.ET on Monday, December 9, 2019.
    • 06 Nov 2019 According to a Precision Biosciences media release, updated data, including from patients treated at Dose Level 2 will be presented during the 61st Annual Meeting of the American Society of Hematology (ASH). Data from patients treated with PBCAR0191 at Dose Level 1 is available on the ASH conference website data from patients treated with PBCAR0191 at Dose Level 1 is available on the ASH conference website (https://www.hematology.org/Annual-Meeting/Abstracts).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top